Bladder Cancer

P3, N=130, Active, not recruiting, Fidia Farmaceutici s.p.a. | Recruiting --> Active, not recruiting

P1, N=156, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting

P=N/A, N=126, Completed, Abramson Cancer Center at Penn Medicine | Enrolling by invitation --> Completed | N=90 --> 126

P2, N=56, Not yet recruiting, The Netherlands Cancer Institute

Integrating CNV and DNA methylation profiling from urinary DNA provides a powerful and noninvasive molecular framework for NMIBC surveillance. By combining early epigenetic changes with genomic instability signals, this approach enhances recurrence risk assessment and enables earlier detection compared with conventional cystoscopy. It offers a practical route toward personalized and adaptive post-treatment monitoring of NMIBC.

Our findings demonstrate that CDH1 polymorphisms and haplotype structures are potential modulators of UBC recurrence. Furthermore, the identification of repetitive elements in crucial genomic segments highlights a new layer of transcriptional regulation, offering promising approaches for the prognostic stratification and molecular targeting of bladder cancer.

We provide a quantitative framework showing that ≥77 genes and ≥3-mm tissue diameter regions preserve predictive spatial signal at scalable throughput. The registration details of the trial are EudraCT 2017-002246-68.

Our findings indicate distinct and compartment-specific roles for CD39 and CD73 in MIBC. They suggest that high CD73 expression in tumor cells and low CD39 expression in stromal cells are negative prognostic indicators and potential therapeutic targets in MIBC.

P2, N=163, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed

P2, N=75, Not yet recruiting, Fudan University

Following a multidisciplinary team discussion, the patient was commenced on systemic chemotherapy and bone-targeted therapy for presumed colorectal carcinoma. This case highlights the diagnostic complexity associated with malignancy in reconstructed urinary tracts and emphasises the need for long-term surveillance in this patient population.

Finally, molecular docking, proteomic profiling, and Drug Affinity Responsive Target Stability (DARTS) assays prioritized Curcumin as a candidate compound potentially associated with PSMG1 targeting. Overall, our findings indicate that the H3K18la-PSMG1 axis may participate in BCa progression and support further evaluation of Curcumin in PSMG1-associated therapeutic strategies.